Ilaris 150 mg (Canakinumab SOLUTION) 150 MG

ILARIS 150 MG is a subcutaneous solution containing canakinumab, used for managing inflammatory conditions. This medication is designed to target specific proteins involved in the body's immune response.

Strength

150 MG

Manufacturer / TM Owner

NOVARTIS PHARMACEUTICALS CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

ILARIS 150 MG is primarily used for the treatment of certain inflammatory conditions. Canakinumab works by targeting specific proteins that play a role in the body's immune response, helping to reduce inflammation. This medication is often prescribed for conditions where excessive inflammation occurs, such as in autoimmune disorders.

Side Effects

Common effects of ILARIS 150 MG may include injection site reactions, such as redness, swelling, or itching. Some individuals might experience fatigue, headache, or upper respiratory infections. These effects vary among users and are not exhaustive.

Precautions & Warnings

ILARIS 150 MG should be handled with care, following the healthcare provider's instructions. It is important to store the medication properly and use it as directed. Individuals with known allergies to canakinumab or any of its components should avoid using this medication.

Avoid Interactions

ILARIS 150 MG may interact with other medications, including those that affect the immune system. It is advisable to consult a healthcare provider before combining it with other treatments. Alcohol and certain supplements might also influence its effectiveness or side effects.

Frequently Asked Questions

ILARIS 150 MG is used to manage certain inflammatory conditions by targeting specific proteins involved in the immune response.

ILARIS 150 MG is administered subcutaneously, meaning it is injected under the skin.

Common effects may include injection site reactions, fatigue, headache, and upper respiratory infections.

It is important to consult a healthcare provider before combining ILARIS 150 MG with other medications, as interactions may occur.

Individuals with known allergies to canakinumab or any of its components should avoid using ILARIS 150 MG.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.